Last reviewed · How we verify
erlotinib plus docetaxel or pemetrexed
At a glance
| Generic name | erlotinib plus docetaxel or pemetrexed |
|---|---|
| Also known as | Tarceva, Taxotere, Alimta |
| Sponsor | Dutch Society of Physicians for Pulmonology and Tuberculosis |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer (PHASE2)
- A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT) (PHASE2)
- A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) (PHASE1, PHASE2)
- 2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC) (PHASE2)
- PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study
- A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer (PHASE2)
- GSK1120212 Rollover Study (PHASE2)
- Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: